ORIC Pharmaceuticals is a stock analyst price targets currently signal double-bagger potential in. See what the excitement around this firm is all about.
The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...
Bayer AG BAYRY reported third-quarter 2024 core earnings of 7 cents per American Depositary Receipt (ADR), which missed the Zacks Consensus Estimate of 17 cents. The company reported earnings of 10 cents...
Regeneron Pharmaceuticals, Inc. REGN reported better-than-expected third-quarter results despite lower sales from its lead drug, Eylea. Revenues climbed 11% to $3.72 billion, driven by growth in Eylea...
Novartis NVS announced that the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (EMA) recommended granting approval to the breast cancer drug Kisqali (ribociclib)...
Bayer BAYRY announced that it has submitted a marketing authorization application (MAA) to the European Medicines Agency (“EMA”) for its pipeline candidate elinzanetant.The MAA is seeking approval...
Roche RHHBY announced that the FDA has approved pipeline candidate, inavolisib, for the treatment of breast cancer, under the brand name Itovebi.The drug is approved in combination with Pfizer’s Ibrance...
Shares of Regeneron Pharmaceuticals, Inc. REGN have gained 13.5% in the year so far against the industry’s decline of 2.8%.The stock has outperformed the sector during this timeframe but underperformed...
For Immediate ReleaseChicago, IL – October 8, 2024 – Today, Zacks Equity Research Eli Lilly LLY, AstraZeneca AZN, Pfizer PFE, Sanofi SNY and Bayer BAYRY.Industry: Big PharmaLink: https://www.zacks.com/commentary/2346520/5-large-drug-stocks-to-watch-from-a-thriving-industryThe...
The drug and biotech industry has done well this year, driven by increased mergers and acquisitions (M&A), the launch of promising new medicines and pipeline successes. Obesity drugs of Novo Nordisk and...